Selected article for: "international license and severe patient"
Author: Eric Anthony Coomes; Hourmazd Haghbayan
Title: Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis
  • Document date: 2020_4_3
    • ID: nadcsiii_29
    Snippet: . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Table 3) . Of these, all are based in China; one has since been cancelled by the principal investigator and one is planned but not yet recruiting. Two of the studies underway are multi-centre RCTs, with a third RCT pending recruitment. The cumulative anticipated sample size for the four plan.....
    Document: . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Table 3) . Of these, all are based in China; one has since been cancelled by the principal investigator and one is planned but not yet recruiting. Two of the studies underway are multi-centre RCTs, with a third RCT pending recruitment. The cumulative anticipated sample size for the four planned studies will be n=518 and the methodological designs are complementary in target patient populations (all-comers, allcomers with elevated IL-6, severe cases with elevated IL-6, and severe cases with elevated IL-6 meeting diagnostic criteria for grade 2-3 CRS) and comparators (supportive therapy, favipiravir, continuous renal replacement therapy).

    Search related documents:
    Co phrase search for related documents
    • cc NC ND International license and plan study: 1
    • continuous renal replacement therapy and patient population: 1, 2, 3, 4
    • continuous renal replacement therapy and renal replacement therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • International license and patient population: 1
    • International license and plan study: 1
    • methodological design and patient population: 1
    • patient population and plan study: 1
    • patient population and renal replacement therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • plan study and recruit plan: 1
    • plan study and renal replacement therapy: 1
    • principal investigator and renal replacement therapy: 1